Sudeepa Bhattacharyya Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

Arkansas State University

Last publication 2025 Last refreshed 2026-05-16

faculty

26 h-index 114 pubs 3,195 cited

Research Areas

Links

ORCID Lab Website

OverviewAI-generated summary

Sudeepa Bhattacharyya's research focuses on understanding the complex biological mechanisms underlying major depressive disorder and anxiety. Bhattacharyya investigates the role of metabolites, such as acylcarnitines and bile acids, in the pathobiology of these conditions and their association with symptom profiles and diagnostic status. This work also explores the influence of gut microbiome-derived metabolites and medication use on these mental health conditions.

Bhattacharyya's scholarly output includes over 114 publications, with a citation count exceeding 3,100 and an h-index of 26. This body of work has garnered federal funding, including a $99,906 NSF grant for campus cyberinfrastructure modernization, where Bhattacharyya served as Co-PI. Collaborations include extensive work with researchers from the University of Arkansas for Medical Sciences, such as Melody Greer (14 shared publications), Fred Prior (5 shared publications), Kevin W. Sexton (3 shared publications), and Joseph VanScoy (3 shared publications).

Additional research interests extend to computational approaches, as indicated by work on natural language processing for clinical discharge summaries and the development of models for concept compilation. Bhattacharyya maintains an active lab website, showcasing ongoing research activities.

Metrics

h-index: 26
Publications: 114
Citations: 3,195

Selected Publications

Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort (2025)

10 citations DOI OpenAlex
Evaluating maternal drug use disparities, risk factors and outcomes in Northeast Arkansas: a pre, during, and post-COVID-19 pandemic analysis (2025)

1 citation DOI OpenAlex
Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder (2025)

4 citations DOI OpenAlex
Medication use is associated with distinct microbial features in anxiety and depression (2025)

9 citations DOI OpenAlex
Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort (2024)

DOI OpenAlex
Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder (2024)

1 citation DOI OpenAlex
Medication Use is Associated with Distinct Microbial Features in Anxiety and Depression (2024)

3 citations DOI OpenAlex
Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort (2024)

DOI OpenAlex
Social Determinants of Health Data Quality at Different Levels of Geographic Detail (2023)

8 citations DOI OpenAlex
Social Determinants of Health Data Quality at Different Levels of Geographic Detail (2023)

3 citations DOI OpenAlex
Repeatable enhancement of healthcare data with social determinants of health (2022)

3 citations DOI OpenAlex
Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety—A Role for Bile Acids (2022)

65 citations DOI OpenAlex
Covid-19 Positivity Differences Among Patients of a Rural, Southern US State Hospital System Based on Population Density, Rural-Urban Classification, and Area Deprivation Index (2022)

4 citations DOI OpenAlex
Metabolomic and inflammatory signatures of symptom dimensions in major depression (2022)

95 citations DOI OpenAlex
Automated Enhancement and Curation of Healthcare Data (2022)

DOI OpenAlex